- Home
- DHIL vs IMAB Comparison
DHIL vs IMAB Comparison
Compare DHIL & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- IMAB
- Stock Information
- Founded
- DHIL 1990
- IMAB 2014
- Country
- DHIL United States
- IMAB United States
- Employees
- DHIL N/A
- IMAB N/A
- Industry
- DHIL Investment Managers
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- IMAB Health Care
- Exchange
- DHIL Nasdaq
- IMAB Nasdaq
- Market Cap
- DHIL 392.1M
- IMAB 384.6M
- IPO Year
- DHIL 1995
- IMAB 2020
- Fundamental
- Price
- DHIL $141.40
- IMAB $3.65
- Analyst Decision
- DHIL
- IMAB Strong Buy
- Analyst Count
- DHIL 0
- IMAB 5
- Target Price
- DHIL N/A
- IMAB $6.80
- AVG Volume (30 Days)
- DHIL 25.5K
- IMAB 1.7M
- Earning Date
- DHIL 11-03-2025
- IMAB 11-02-2025
- Dividend Yield
- DHIL 4.24%
- IMAB N/A
- EPS Growth
- DHIL 21.42
- IMAB N/A
- EPS
- DHIL 17.58
- IMAB N/A
- Revenue
- DHIL $151,281,009.00
- IMAB N/A
- Revenue This Year
- DHIL N/A
- IMAB N/A
- Revenue Next Year
- DHIL N/A
- IMAB N/A
- P/E Ratio
- DHIL $8.02
- IMAB N/A
- Revenue Growth
- DHIL 6.29
- IMAB N/A
- 52 Week Low
- DHIL $122.32
- IMAB $0.60
- 52 Week High
- DHIL $173.25
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- DHIL 45.31
- IMAB 44.20
- Support Level
- DHIL $139.55
- IMAB $3.20
- Resistance Level
- DHIL $143.00
- IMAB $4.64
- Average True Range (ATR)
- DHIL 2.41
- IMAB 0.38
- MACD
- DHIL -0.24
- IMAB -0.16
- Stochastic Oscillator
- DHIL 26.36
- IMAB 27.11
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).